Competitor Landscape: Inflammatory Bowel Disease (IBD)

Competitor Landscape: Inflammatory Bowel Disease (IBD)

Summary

Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the IBD market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

- Given the significant time difference between primary completion dates of VISIBLE 1 (UC) and VISIBLE 2 (Crohns disease), Takeda will likely file the subQ formulation of VDZ in UC before filing in Crohns disease, in order to mitigate against the risk of ustekinumab becoming established in UC
- RHB-104 will likely be the first antibiotic approved in Crohns disease, but RedHill BioPharma announced in the results webcast that it will likely need to conduct an additional Phase III trial to support a New Drug Application (NDA) in the US, which will delay its approval timeline
- Allergan is the second company, after Genentech (with UTTR1147A), to use vedolizumab as an active comparator in a Phase II UC trial, with the design suggesting brazikumab could proceed directly to Phase III if it is successful at Phase II.

Scope

- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Overall IBD (Biologic & Small Molecule) Landscape
Key Events & Landscape Updates
Pipeline Landscape
Order of Entry
Overview
Events & Milestones: H1 2018-H2 2019
Key Competitor Market Entry Strategies
Approved Product Development Landscape
Lifecycle Development
Key Competitor Direction of Travel
Appendix

Competitor Landscape: Inflammatory Bowel Disease (IBD)

Competitor Landscape: Inflammatory Bowel Disease (IBD)Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the IBD market, analysis of current & potential future product positioning, and forecast approval

USD 6400 View Report

Competitor Landscape: Lupus

Competitor Landscape: LupusSociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter)

USD 6400 View Report

Competitor Landscape: Lupus

Competitor Landscape: LupusSociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter)

USD 6400 View Report

Competitor Landscape: HIV

Competitor Landscape: HIVSociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the HIV market, analysis of current & potential future product positioning, and forecast approval dates (by quarter)

USD 6400 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available